On this work, we modeled a rare neurological auto-immune disease called Aicardi-Goutieres Syndrome (AGS), caused by mutations in the TREX1 gene. AGS is characterized by a dramatic neuronal loss, leading to a life-long disability condition. The lack of robust animal models has blocked the understanding of the pathology and potential treatments. Using pluripotent stem cells, we create the first human model of AGS. When these cells were differentiated into neurons, we observed a massive cell death. On the other hand, astrocytes derived from the same donor cells survived, but displayed a clear inflammatory reactivity response by releasing interferon. We showed that the interferon response from astrocytes was affecting neuronal survival. When investigating the causes of the inflammatory response, we focused on the accumulation of nucleic acid on the cytoplast of astrocytes. The identity of these nucleic acid was LINE-1 retrotransposons. LINE-1 or L1s are repetitive sequences on the human genome that can autonomously retrotranspose using reverse transcriptase. To prove that astrocytes were recognizing L1s as intruders, we treated these cells with HIV reverse transcriptase inhibitors. The treatment not only reduce the inflammatory response, but also rescued neuronal death. More importantly, we also treated brain organoids carrying TREX1 mutations and we could rescue the microcephalic phenotype, revealing a novel therapeutic opportunity for AGS.